GlaxoSmithKline’s combination vaccine Kinrix (DTaP/IPV vaccine) has been approved by the FDA for the immunization of children 4-6 years of age against diphtheria, tetanus, pertussis and polio. This approval is based on clinical studies that demonstrate that a single injection of Kinrix offers similar protection to separately administered injections of DTaP and IPV vaccine, with a comparable safety profile.

Kinrix is expected to be available in mid-July 2008.

For more information call (888) 825-5249 or visit